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DFSP is a locally invasive, slow-growing tumor of the subcutaneous tissue that rarely metastasizes but recurs
frequently after surgical excision. We report herein a case of highly recurrent, locally invasive DFSP that failed both
postoperative radiation therapy and complete trial of Imatinib, but was successfully treated with Sorafenib, which
showed unprecedented response.Background
Dermatofibrosarcoma Protuberans (DFSP) is a locally
invasive and slow-growing tumor of the subcutaneous
tissue. It rarely metastasizes. It was first described in
1924 as a progressive and recurrent dermatofibroma [1].
DFSP has an annual incidence of only 0.8 cases per mil-
lion and presents typically at mid-adult life with a slight
male predominance [2]. The trunk and proximal extrem-
ities are the most frequent locations of the disease, but it
can occur at any other site.
DFSPs rarely progress to a high-grade fibrosarcoma-
tous component [3]. One to 4% of patients will develop
distant metastasis, typically many years after the devel-
opment of the initial lesion [4].
According to the NCCN Clinical Practice Guidelines in
Oncology, The gold standards treatment is complete surgi-
cal excision with appropriate reconstruction [5]. Imatinib
is approved for treatment of advanced disease [6-17].
When resection is limited or incomplete, or margins are
positive recurrence rate is high [18-20]. In these cases, adju-
vant radiation therapy is recommended as well as Imatinib
based treatment or enrollment in a clinical trial [5].
We report hereafter a case of highly recurrent, locally
invasive DFSP that failed both postoperative radiation
therapy and treatment with Imatinib at 400 mg initially
that was then increased to 800 mg. The patient received
Sorafenib off label and showed an unprecedented re-
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A 36 year-old gentleman presented with a left shoulder
skin lesion that was initially totally excised. Histopath-
ology reported Dermatofibrosarcoma Protuberans (DFSP).
He relapsed sometime after this initial resection and
underwent a second surgery followed by several other
relapses and re-resections and 2 courses of radiation ther-
apy and ended up having multifocal disease sites on the
upper torso, the shoulder and neck. Plastic surgeons
exhausted all available skin that could be spared for flaps
and reconstruction. After the third relapse and the first
round of radiotherapy, he received Imatinib at 400 mg
daily with a positive response lasting for about 2 years.
Upon progression, he was offered Imatinib 800 mg daily
with non negligible side effects and no response.
All pathology readings of repeated excisions were
reported as DFSP except for one time, where the pres-
ence of cellular pleomorphism and the lack of CD 34 ex-
pression raised the possibility of transformation into a
fibrosarcoma. Margins following his third resection were
always positive.
There was no FISH analysis or RT-PCR or molecular
studies ordered to detect the presence of the typical
chromosomal translocation t(17;22)(q21;q13) in the tumor
of this patient, resulting in the chimeric gene COL1A1-
PDGFB.
The patient ended up with left upper extremity ampu-
tation at the level of the shoulder and was referred to us.
He presented with massive and bulky soft tissue le-
sions on his upper torso and in the neck. A contrast en-
hanced CT scan also revealed large mediastinal masses
and post obstructive pneumopathy on the left.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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available for us on compassionate use. A dramatic re-
sponse was seen after only few days of treatment (Figures 1
and 2). The patient received Sorafenib 800 mg daily for 5
months without recurrence or progression of the tumor.
There was no significant side effect reported beside mod-
erate fatigue, and dehiscence of prior surgical wounds.
However, he suffered from recurrent pulmonary infections
despite decompression of his left main bronchus since
attaining a very good partial response, and unfortunately
passed away after an episode of septic shock. He remained
progression free during the whole treatment time. Ther-
apy was discontinued only one week prior to his death.
Discussion
DFSP accounts for 2 to 6% of all soft tissue sarcomas
[21,22]. It is the most frequent skin sarcoma.
The tumor involves most frequently the trunk (42-72%),
the proximal extremities (16%-30%), and the head and
neck (10-16%) especially the scalp [23-28].
The initial presentation of DFSP is a skin lesion de-
scribed as a single, raised, red to bluish, firm cutaneous
nodule or plaque with surrounding discoloration [29].
The lesion is painless and indurated, but is extremely in-
filtrative and has a locally destructive growth that can in-
vade the underlying structure such as fascia, muscles or
bones [18-20,30]. The tumor is often covered by a brown-
yellow, red-tinged, sclerodermiform or teleangiectatic and
atrophic skin [20]. At the initial stages of the disease, his-
tory of trauma, burn or surgical scar is often found.
At advanced stages, the tumor can ulcerate, bleed, and
become painful, as reported in our case.
Near to 90% of DFSP are considered to be tumors of
low-grade malignancy [4]. Histologically, DFSP is iden-
tified by a pattern of monomorphous proliferation of cy-
tological bland spindle cells with a visible storiform or
whorled (rushmat-like) architecture [4,23,31]. Other char-
acteristic features are low mitotic activity and deep, honey-
comb infiltration into subcutaneous adipose tissue [30].Figure 1 Radiological response to Sorafenib.The expression of CD34 is almost a consistent finding
and it is extremely useful in differentiation of DFSP from
benign fibrous histiocytoma [32], dermatofibroma and
other soft tissue tumors [33-35]. The sensitivity of CD34
staining in DFSP ranges from 84 to 100% [30].
Cryptogenic abnormalities are also distinguishable char-
acteristics of DFSP since more than 90% of cases have
supernumerary ring chromosomes or a unique translo-
cation involving chromosomes 17 and 22 as in t(17;22)
(22;q13) [36-41]. This abnormality results in a constitutive
stimulation of the platelet-derived growth factor recep-
tor (PDGFR) with subsequent enhancement of the tumor
cell growth [6,28]. Furthermore, among all the family of
PDGF receptors, this translocation is responsible for the
activation of PDGFR-beta [42].
Distant metastasis is rarely observed, with a rate of
4-6%, predominantly to the lungs [20,30].
DFSP can transform, especially in the recurring forms,
into fibrosarcomatous DFSP (FS-DFSP), a tumor with
higher invasion and malignancy potential [3,4,28,43]. It
usually requires a more intensive treatment approach.
The optimal and the mainstay treatment of DFSP, re-
gardless of its location, is wide and deep excision with
adequate tumor-free margins. The proper excision with
clean margins is directly related to the risk of recurrence
of the disease despite adjuvant therapy [18,19,44,45].
The involvement of the deep fascia and muscles requires
excision of these structures [18,19].
The most significant prognostic factor in patients with
DFSP has proved to be the extent of surgical resection.
The success of the initial surgical excision has a major
effect on the outcome as well. In fact, if this procedure
fails and hence, the tumor recurs, it could lead to an un-
controllable local growth, as seen in our case.
Due to its infiltrative nature, DFSP is characterized
by a high recurrence rate varying in the literature from
10-80% [18]. The risk of recurrence was 41% when the
excision margin was less than 2 cm and 24% when it
was equal to or higher than 2 cm [44].
Figure 2 Clinical improvement and dramatic shrinking of the tumor.
Kamar et al. Clinical Sarcoma Research 2013, 3:5 Page 3 of 5
http://www.clinicalsarcomaresearch.com/content/3/1/5DFSP is considered as one of the radiosensitive tu-
mors. Earlier studies suggested that additional postoper-
ative RT reduces the risk of local recurrence in patients
with questionable or positive surgical margins [46,47].
When complete surgical resection is unachievable, RT is
indicated [46,48]. RT can reduce the morbidity or func-
tional impairment associated with extensive resection.
As seen in the present case, locally recurrent DFSP
can be devastating. Salvage by further resection increases
the risk of functional deficits and metastatic disease.
Since the recent identification of the significance of
PDGFR activation in the DFSP pathogenesis, the effective-
ness of targeted chemotherapy by inhibition of the PDGFR
protein-tyrosine kinase has been evaluated. Imatinib, a
small adenosine triphosphate analog is a selective PDGFR
tyrosine kinase-inhibitor. It was approved for the treat-
ment of DFSP at a dose of 800 mg daily. Such dose is eas-
ily reached orally, with non negligible side effects. Some
clinical reports showed Imatinib induced regression in pa-
tients with recurrent or metastatic DFSP [6-17].
However, response was not consistent in all cases as
described in our patient.
To date, no other targeted therapy for DFSP has been
reported.
We report the first case of recurrent and extensive
DFSP successfully treated with Sorafenib after failure of
postoperative radiation therapy and refractory to treat-
ment with 800 mg of Imatinib.
Sorafenib is a small molecule B-raf and vascular endo-
thelial growth factor (VEGF) receptor inhibitor. It has
shown great value in the treatment of angiosarcomas
[49] Maki et al., and some other specific sarcoma sub-
types (e.g. peripheral-nerve sheath tumors (MPNST) with
loss of NF1 and activation of the ras-raf signaling path-
way) [50-52].
Since it has been reported to have an important role
in the treatment of some sarcomas, we elected Sorafenib
as a salvage option for our patient. The response wasremarkable. The tumor almost totally regressed and the pa-
tient improved clinically. This case suggests that Sorafenib
could be an important targeted therapy for DFSP especially
in case of recurrence or metastasis.
Conclusion
Invasive DSFP could be uncontrollable and challenging to
cure. We present a case of recurrent and infiltrative DSFP
that failed all conventional therapeutic options. Sorafenib
was administered as final resort with impressive results.
This is to our knowledge the only reported case of
DFSP treated with Sorafenib after failure of Imatinib.
Sorafenib could represent a therapeutic alternative in
such cases of DFSP.
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